Ibex Medical Analytics vs PathAI (2026)
Ibex sells AI that reads slides; PathAI sells the platform slides are read in. Ibex's Galen Second Read is 510(k) cleared (K241232) to flag prostate biopsies initially called benign, and its breast and gastric solutions are research use only in the United States and CE-IVD marked elsewhere; results return through partner platforms. PathAI's AISight Dx is cleared for primary diagnosis (K243391) with four named scanners and runs PathAI's research use only algorithms beside partners'. In May 2026 PathAI agreed to be acquired by Roche.
- You want an FDA clearance that covers the AI itself.
- You want results inside the image management and laboratory systems you already run.
- Your security review wants the business associate addendum and subprocessor list published.
- You need a cleared platform for primary diagnosis.
- You want PathAI's and partners' algorithms in one workspace.
- You run MASH trials, where AIM-MASH AI Assist is qualified.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Ibex Medical Analytics and PathAI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Ibex Medical Analytics | PathAI |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2016 | 2016 |
| Headquarters | Tel Aviv, Israel | Boston, Massachusetts, United States |
| Website | ibex-ai.com | pathai.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
PathAI
-
Product / capability
PathAI released version 2.21 of its AISight Dx digital pathology platform, introducing customizable case dashboards, an AI impressions widget, and expanded metadata support for bulk slide ingestion.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Cancer diagnostics company selling Galen, AI applications that analyze H&E whole slide images for prostate, breast and gastric cancer and return results into laboratories' existing image management and laboratory systems through partners including Roche, Philips, Proscia and Sectra.
Source: AI Health Index, September 2026
Digital pathology company selling the AISight image management system and its own AI algorithms. AISight Dx is FDA 510(k) cleared (K243391, June 2025) for primary diagnosis with four named scanners and CE-IVD marked in Europe, and is deployed at laboratories including Labcorp and MedStar Health.
Source: AI Health Index, September 2026
Questions buyers ask
How do Ibex Medical Analytics and PathAI work with the EHR?
For Ibex Medical Analytics, the 510(k) summary describes the cleared product ingesting slides automatically from the scanner and image management system, with the diagnosis documented in another system such as the LIS.
The image management pages say AISight is interoperable with most major laboratory information systems and with Hamamatsu, Leica, Roche and Philips scanners, and that AISight Link, PathAI's open API, powers LIS integration and embeds partner algorithms in the viewer. The pages name no LIS product, no standard such as HL7 or DICOM, and no integration documentation. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are Ibex Medical Analytics and PathAI priced and sold?
In Ibex Medical Analytics' case, the company's pages carry no list price, per case or per slide rate, tier structure or worked example for any Galen application, and commercial contact runs through a contact form.
The product pages carry no license fee, per case or per slide rate, tier structure or worked example for AISight, AISight Dx, PathAI's own algorithms or the partner algorithms offered through the platform, and commercial contact runs through a demo request or a dedicated sales address. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Ibex Medical Analytics and PathAI handle patient data?
The Data Protection Addendum (last updated February 2026), linked from the trust center, lets Ibex delete customer personal data 21 days after receipt unless a different period is agreed in the purchase confirmation, and requires deletion from Ibex's and its sub-processors' systems at termination or on written request.
The privacy notice (effective 13 February 2025), which covers PathAI's platforms, says PathAI requests only the minimum information needed and retains it only as long as necessary to provide the services or for compatible purposes, including providing additional services. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Ibex Medical Analytics and PathAI cover?
For Ibex Medical Analytics, the company sells Galen for prostate, breast and gastric biopsies and says its models were developed from more than 10 million slides from multiple pathology institutes.
With PathAI, the biomarker algorithms name their indications and supported antibody clones (PD-L1 in non-small cell lung, head and neck, melanoma and urothelial cancer; HER2, ER, PR and Ki-67 in breast), and the menu extends to ulcerative colitis and dermatopathology, but these are research use only in the United States with no validation named on the product pages. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
The regulatory positions cover different things: Ibex's clearance covers an algorithm for one indication on one scanner, and PathAI's covers the image management system, not its algorithms. PathAI's Roche acquisition was pending at review. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.